Real-World Treatment Study of Koselugo (Selumetinib)
Study identifier:D1346R00009
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Will Be Recruiting
Official Title
Real-World Treatment Study of Koselugo (Selumetinib)
Medical condition
Neurofibromatosis 1, Neurofibroma, Plexiform
Phase
N/A
Healthy volunteers
No
Study drug
-
Sex
All
Estimated Enrollment
150
Study type
Observational
Age
3 Years - 18 Years
Date
Study Start Date: 01 Jun 2024
Estimated Primary Completion Date: 30 Sept 2031
Estimated Study Completion Date: 30 Sept 2031
Study design
Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verification:
Verified 01 Apr 2024 by AstraZeneca
Sponsors
AstraZeneca
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
